Psychotherapy‐Supported Lisdexamfetamine Tapering in Binge‐Eating Disorder: Spotlighting a Critical Research Gap
International Journal of Eating Disorders · 2026-06 · 59 (6) · 1246-1256
DOI: 10.1002/eat.70071 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Eating Disorders, online erschienen am 27.02.2026. Verfasst von Cristin D Runfola und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Binge-Eating Disorder, Cognitive Behavioral Therapy, Drug Tapering. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Objective
This spotlight highlights a critical gap in the research literature. Despite evidence that combined cognitive‐behavioral therapy (CBT) and lisdexamfetamine dimesylate (LDX) for binge‐eating disorder (BED) is superior to either intervention alone, no studies have examined whether psychotherapy can support gradual tapering off LDX while preserving treatment gains. While evidence shows higher rates of binge‐eating relapse after LDX discontinuation, long‐term use is complicated by concerns regarding side effects (e.g., hypertension), misuse‐potential, cost, and/or drug interactions. Unfortunately, without current research on optimal LDX tapering strategies, clinicians lack guidance at a critical juncture.
Method
Given the absence of studies that have examined tapering psychiatric medications in BED, let alone any established protocols for doing so, the authors offer two spotlighted examples to illustrate the potential utility and clinical challenges of therapist guided LDX discontinuation during psychotherapy for BED.
Results
The spotlighted examples demonstrate that binge relapse can be avoided through gradual LDX tapering embedded within psychotherapy, with treatment gains sustained at long‐term follow‐up (up to 5 years after LDX discontinuation).
Discussion
This spotlight highlights the need for further research to investigate discontinuing LDX and whether gradual, therapist‐supported tapering might enable the superiority of combined treatment to be sustained. Spotlighted examples were used to illustrate the conceptual framework and clinical relevance of this spotlight's central argument: that systematically evaluating optimal approaches to medication discontinuation, specifically LDX for BED, is an idea worth researching. We describe potential obstacles and limitations while also highlighting clinical or policy implications for future study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
ORCID-Profile: Cristin D Runfola, Debra L Safer
Zitieren
APA
Runfola, C. D., & Safer, D. L. (2026). Psychotherapy‐Supported Lisdexamfetamine Tapering in Binge‐Eating Disorder: Spotlighting a Critical Research Gap. International Journal of Eating Disorders, 59(6), 1246-1256. https://doi.org/10.1002/eat.70071
Vancouver
Runfola CD, Safer DL. Psychotherapy‐Supported Lisdexamfetamine Tapering in Binge‐Eating Disorder: Spotlighting a Critical Research Gap. International Journal of Eating Disorders. 2026;59(6):1246-1256. doi:10.1002/eat.70071
BibTeX
@article{Runfola2026,
author = {Runfola, Cristin D and Safer, Debra L},
title = {Psychotherapy‐Supported Lisdexamfetamine Tapering in Binge‐Eating Disorder: Spotlighting a Critical Research Gap},
journal = {International Journal of Eating Disorders},
year = {2026},
volume = {59},
number = {6},
pages = {1246--1256},
doi = {10.1002/eat.70071}
}
EUVIMED